# New Glioblastoma clinical trials: 226 posted since Nov 2024

Updated October 30, 2026.

226 clinical studies in glioblastoma were first posted on ClinicalTrials.gov from November 12, 2024 to October 30, 2026; 49 have an industry sponsor and 200 are recruiting or about to. The newest, NCT07908147, was posted on October 30, 2026: Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study (Olivia Newton-John Cancer Research Institute).

## The full list

New Glioblastoma clinical trials: 226 rows for $11.30, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 10 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/glioblastoma

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 226
- Industry sponsored: 49
- Recruiting or not yet: 200
- Latest posted: October 30, 2026

## Newest trials

The newest 100 of 226, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07908147 | Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study | Olivia Newton-John Cancer Research Institute | Early phase 1 | Not yet recruiting | IDH Wildtype Glioblastoma, Glioblastoma (GBM) | 12 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908147) |
| October 28, 2026 | NCT07902037 | A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) | Siren Biotechnology | Phase 1/2 | Not yet recruiting | Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma, Diffuse Hemispheric Glioma | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902037) |
| October 22, 2026 | NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | German Cancer Research Center | Phase 2 | Not yet recruiting | Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | 216 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888647) |
| October 20, 2026 | NCT07884344 | Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma | Macarena De La Fuente, MD | Early phase 1 | Recruiting | Glioblastoma | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884344) |
| October 14, 2026 | NCT07873996 | Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma | Beijing Tiantan Hospital | Phase 2/3 | Not yet recruiting | Newly Diagnosed Glioblastoma, IDH-wildtype | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873996) |
| October 9, 2026 | NCT07867886 | An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM | Boston Scientific Corporation | Not applicable | Not yet recruiting | Recurrent Glioblastoma | 30 | France, Germany, Netherlands, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867886) |
| October 8, 2026 | NCT07865195 | Diffuse Gliomas in Reunion Island: Establishment of an Epidemiological, Clinical-biological and Socio-anthropological Cohorte | Centre Hospitalier Universitaire de la Réunion | Observational | Recruiting | Glioblastoma | 214 | Reunion | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865195) |
| October 7, 2026 | NCT07862647 | TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma | Alpheus Medical, Inc. | Phase 1 | Recruiting | Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862647) |
| October 5, 2026 | NCT07859059 | Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma | University of Nebraska | Phase 1/2 | Not yet recruiting | High Grade Glioma, Glioblastoma, Gliosarcoma | 41 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859059) |
| October 1, 2026 | NCT07852975 | GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic... | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not applicable | Not yet recruiting | Recurrent Glioma (Glioblastoma Multiforme) | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852975) |
| September 22, 2026 | NCT07832734 | Metabolomics and Transcriptomics of Low- and High-Grade Gliomas | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | Observational | Recruiting | IDH Wildtype Glioblastoma, IDH Mutant Lower-Grade Gliomas | 220 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832734) |
| September 22, 2026 | NCT07832448 | Microsurgical Resection Combined With Photodynamic Therapy for Recurrent Glioblastoma | Yonggao Mou | Not applicable | Active not recruiting | Recurrent Glioblastoma (WHO-Grade IV Glioma) | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832448) |
| September 21, 2026 | NCT07831772 | REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma | University of Minnesota | Not applicable | Recruiting | Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor | 4 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831772) |
| September 21, 2026 | NCT07831369 | VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | Inova Health Care Services | Phase 2 | Recruiting | Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4 | 52 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831369) |
| September 21, 2026 | NCT07831187 | Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | First Affiliated Hospital of Wenzhou Medical University | Phase 1/2 | Not yet recruiting | Glioblastoma | 96 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831187) |
| September 21, 2026 | NCT07831161 | Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma | Dong-A University Hospital | Not applicable | Not yet recruiting | Recurrent Glioblastoma | 60 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831161) |
| September 15, 2026 | NCT07821112 | Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® | University of California, Irvine | Phase 2 | Not yet recruiting | Glioma, Glioblastoma, GBM, Glioma, Malignant, Astrocytoma, Oligodendroglioma, Elderly Glioblastoma, Elderly GBM | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821112) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| August 27, 2026 | NCT07791264 | FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma | City of Hope Medical Center | Phase 1 | Not yet recruiting | Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791264) |
| August 27, 2026 | NCT07789379 | Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma | Wei Jiang | Phase 2 | Not yet recruiting | Glioblastoma | 94 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789379) |
| August 26, 2026 | NCT07788430 | Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study | Institut Claudius Regaud | Not applicable | Not yet recruiting | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | 120 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788430) |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| August 21, 2026 | NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Early phase 1 | Not yet recruiting | MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma | 22 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778602) |
| August 20, 2026 | NCT07775534 | Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients | City of Hope Medical Center | Not applicable | Recruiting | Glioblastoma | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775534) |
| August 18, 2026 | NCT07769918 | Hypoxia-targeted Radiotherapy Boost for GBM | NYU Langone Health | Not applicable | Not yet recruiting | Glioblastoma (GBM) | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07769918) |
| August 13, 2026 | NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient)... | BreakBio Corp | Phase 1/2 | Not yet recruiting | Glioblastoma (GBM) | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762716) |
| August 11, 2026 | NCT07758062 | Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma | Tianjin Medical University General Hospital | Phase 2 | Not yet recruiting | Glioblastoma | 140 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758062) |
| August 10, 2026 | NCT07754734 | STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation | Dongguan People's Hospital | Phase 2 | Not yet recruiting | Glioma, Glioblastoma (GBM), MGMT-Methylated Glioblastoma | 138 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754734) |
| August 7, 2026 | NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal... | Jubilant Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM) | 113 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751744) |
| August 5, 2026 | NCT07748299 | NuvOx Expanded Access | NuvOx LLC | Not applicable | Available | Glioblastoma, Respiratory Distress Syndrom, Ischemic Stroke, Hypoxic Conditions | Not listed |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748299) |
| July 31, 2026 | NCT07739017 | OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma | Olivia Newton-John Cancer Research Institute | Phase 1 | Not yet recruiting | Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma | 54 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739017) |
| July 30, 2026 | NCT07735819 | Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma | Barbara Ann Karmanos Cancer Institute | Phase 2 | Not yet recruiting | Low Grade Glioma, Glioblastoma | 61 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735819) |
| July 29, 2026 | NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma... | Radiomedix, Inc. | Phase 1 | Recruiting | Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC) | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733674) |
| July 28, 2026 | NCT07731555 | Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological... | Patrick Morris | Not applicable | Recruiting | Glioblastoma | 100 | Ireland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731555) |
| July 20, 2026 | NCT07715097 | Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma | Beijing Tricision Biotherapeutics Inc | Phase 2 | Not yet recruiting | Glioblastoma | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715097) |
| July 17, 2026 | NCT07712770 | Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma | Olivia Newton-John Cancer Research Institute | Early phase 1 | Not yet recruiting | Recurrent Glioblastoma IDH Wildtype, Recurrent Glioblastoma | 12 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712770) |
| July 16, 2026 | NCT07708961 | Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma | Mayo Clinic | Phase 2 | Recruiting | Glioblastoma, IDH-Wildtype | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708961) |
| July 8, 2026 | NCT07689721 | ctDNA-Guided Intraventricular Therapy for CNS Malignancies | Alireza Mansouri | Not applicable | Not yet recruiting | Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer, Breast Cancer | 77 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689721) |
| July 1, 2026 | NCT07678138 | Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic... | Huanhu Hospital Affiliated to Tianjin Medical University | Not applicable | Not yet recruiting | Glioblastoma | 9 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678138) |
| June 29, 2026 | NCT07674095 | Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in... | BPGbio | Observational | Active not recruiting | Glioblastoma | 150 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674095) |
| June 29, 2026 | NCT07673679 | GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4 | Deep Learning Institute of Radiological Sciences | Observational | Completed | Glioma, Glioma (Diagnosis), Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 4 | 1,372 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673679) |
| June 26, 2026 | NCT07670455 | Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response | The Leeds Teaching Hospitals NHS Trust | Not applicable | Not yet recruiting | High Grade Gliomas, Hypoxia Brain, Glioblastoma (GBM), Brain Neoplasms, Adult | 25 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670455) |
| June 25, 2026 | NCT07670026 | Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Glioblastoma | 31 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670026) |
| June 25, 2026 | NCT07668869 | TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0) | Prof. Franciszek Lukaszczyk Memorial Oncology Center | Not applicable | Recruiting | Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastoma Multiforme, Adult | 92 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668869) |
| June 24, 2026 | NCT07664579 | Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against... | City of Hope Medical Center | Observational | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm, Metastatic Breast... | 160 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664579) |
| June 16, 2026 | NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Completed | Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma, Head and Neck Cancers, Glioblastoma, Colorectal Cancer... | 1 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651020) |
| June 15, 2026 | NCT07648823 | Dosimetry, Safety, and Efficacy Study of \[177Lu\]Lu-XT771 in Patients With Recurrent Glioblastoma | Beijing Tiantan Hospital | Early phase 1 | Recruiting | Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH... | 5 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648823) |
| June 12, 2026 | NCT07643870 | Human ADME Study of \[14C\]-AZD1390 | AstraZeneca | Phase 1 | Not yet recruiting | Advanced Solid Malignancies | 8 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643870) |
| June 9, 2026 | NCT07636200 | The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer | University of Colorado, Boulder | Not applicable | Recruiting | Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer, Small Cell... | 250 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636200) |
| June 9, 2026 | NCT07635173 | SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas | Shenzhen Zhenxing Medical Technology Co., Ltd | Phase 1 | Completed | Glioma, Glioblastomas (GBM), High Grade Gliomas | 35 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635173) |
| June 9, 2026 | NCT07634575 | Triggered Imaging in Glioblastoma Based on Clinical Outcome Evaluation Compared to Routine: a Feasibility Study | King's College Hospital NHS Trust | Not applicable | Enrolling by invitation | Glioblastoma | 20 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634575) |
| June 5, 2026 | NCT07628647 | Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being | University of Colorado, Denver | Not applicable | Recruiting | Brain Cancer | 64 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628647) |
| June 4, 2026 | NCT07628257 | Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With... | Centre Paul Strauss | Not applicable | Not yet recruiting | Glioblastoma | 80 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628257) |
| June 4, 2026 | NCT07627334 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled... | Medical University of Vienna | Not applicable | Recruiting | Glioblastoma (GBM) | 30 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627334) |
| June 2, 2026 | NCT07620548 | Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas | Washington University School of Medicine | Phase 2 | Not yet recruiting | Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | 99 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620548) |
| June 1, 2026 | NCT07616986 | LITT for Ultra-early GBM Recurrence | Insel Gruppe AG, University Hospital Bern | Not applicable | Recruiting | Glioblastoma (GBM), Glioblastoma - Category | 12 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616986) |
| May 27, 2026 | NCT07608003 | Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis: | Xiangya Hospital of Central South University | Observational | Recruiting | Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem, Glioma, Diffuse... | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608003) |
| May 22, 2026 | NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma | Myosin Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Glioblastoma | 36 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604285) |
| May 15, 2026 | NCT07590726 | PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors | Copenhagen University Hospital, Rigshospitalet | Not applicable | Not yet recruiting | Brain Injuries, Acute, Brain Tumor Adult, Brain (Nervous System) Cancers, Traumatic Brain Injuries, Glioblastom WHO... | 160 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590726) |
| May 14, 2026 | NCT07585851 | Administration of Repurposed Ketoconazole in Glioma Patients | Universitas Padjadjaran | Early phase 1 | Active not recruiting | Diffuse Glioma, Diffuse Glioma, Grade I, Diffuse Glioma, Grade II, Diffuse Glioma, Grade III, Diffuse Glioma, Grade IV | 80 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585851) |
| May 12, 2026 | NCT07579208 | A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor... | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma | 36 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579208) |
| May 6, 2026 | NCT07568782 | Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune... | University Hospital, Lille | Observational | Not yet recruiting | Glioblastoma | 17 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07568782) |
| May 5, 2026 | NCT07567196 | PET-Guided Resection in High-Grade Gliomas | Universita degli Studi di Genova | Observational | Recruiting | Glioma Glioblastoma Multiforme, Glioma, High Grade, Glioma Surgery, Positron-Emission Tomography(PET) | 100 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567196) |
| May 1, 2026 | NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | Masonic Cancer Center, University of Minnesota | Phase 1 | Recruiting | Astrocytoma, Glioblastoma, Progressive Disease | 9 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560865) |
| April 28, 2026 | NCT07553520 | Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients | UNC Lineberger Comprehensive Cancer Center | Not applicable | Withdrawn | Glioblastoma Multiforme, Recurrent Glioma | 0 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553520) |
| April 27, 2026 | NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Recruiting | Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma, Head and Neck Tumors, Glioblastoma, Colorectal Cancer, Melanoma | 26 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552467) |
| April 27, 2026 | NCT07552233 | NK Cell Therapy for Malignant Solid Brain Tumors | Peking University Third Hospital | Not applicable | Recruiting | Malignant Solid Brain Tumors, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Brain Metastasis, Malignant Meningioma | 27 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552233) |
| April 24, 2026 | NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | Beijing Biotech | Phase 1 | Recruiting | Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas, Recurrent Glioblastoma | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551336) |
| April 23, 2026 | NCT07546669 | Efficacy of Zoster Vaccination in Glioblastoma Patients | University Hospital, Essen | Phase 4 | Not yet recruiting | Glioblastoma (GBM) | 230 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546669) |
| April 22, 2026 | NCT07544992 | Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive... | City of Hope Medical Center | Phase 1 | Recruiting | Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544992) |
| April 21, 2026 | NCT07541781 | Sitagliptin in Recurrent/Progressive Grade 4 Glioma | Kailin Yang, MD, PhD | Phase 1 | Recruiting | Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder) | 45 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541781) |
| April 20, 2026 | NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent... | Huashan Hospital | Early phase 1 | Recruiting | Recurrent Glioblastoma | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538128) |
| April 15, 2026 | NCT07532031 | APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas | IRCCS Ospedale San Raffaele | Observational | Not yet recruiting | High-Grade Glioma, Glioblastoma, Brain Tumor Adult | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532031) |
| April 13, 2026 | NCT07524140 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors | Eilean Therapeutics | Phase 1 | Recruiting | Advanced Solid Tumor Cancer, Metastatic Solid Tumor | 60 | Australia, Uzbekistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524140) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| April 13, 2026 | NCT07521657 | Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma | University of Alabama at Birmingham | Phase 2 | Not yet recruiting | Neurofibromatosis 1 (NF1) | 55 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07521657) |
| April 7, 2026 | NCT07515924 | Oral Gallium Maltolate for Recurrent Glioblastoma | Medical College of Wisconsin | Early phase 1 | Not yet recruiting | Glioblastoma | 8 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515924) |
| April 6, 2026 | NCT07512154 | Precision Radiotherapy Enabled by Molecular MRI | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not applicable | Recruiting | Brain Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512154) |
| April 6, 2026 | NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Glioblastoma (GBM) | 38 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511725) |
| March 30, 2026 | NCT07501559 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | Jecho Biopharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Recurrent Glioblastoma Multiforme(GBM) | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501559) |
| March 30, 2026 | NCT07499141 | Use of Fluorescence in Gliomas | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria | Observational | Completed | High Grade Glioma, Glioblastoma, Brain Neoplasms | 41 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499141) |
| March 27, 2026 | NCT07497373 | A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma | Jecho Biopharmaceuticals Co., Ltd. | Phase 1 | Completed | Recurrent Glioblastoma Multiforme(GBM) | 17 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497373) |
| March 25, 2026 | NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | Eben Rosenthal | Early phase 1 | Recruiting | Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493447) |
| March 25, 2026 | NCT07492836 | Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma | Hospital do Coracao | Not applicable | Not yet recruiting | Glioblastoma (GBM) | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492836) |
| March 23, 2026 | NCT07488754 | Local, Targeted Therapy With Alpha Emitter \[225Ac\]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | Medical University of Warsaw | Not applicable | Recruiting | Glioblastoma, High-Grade Glioma (WHO III-IV), Glioblastoma (GBM) | 35 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488754) |
| March 20, 2026 | NCT07485049 | BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors | Nader Sanai | Early phase 1 | Recruiting | Glioblastoma (GBM) | 78 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485049) |
| March 18, 2026 | NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | Beijing Biotech | Phase 1 | Recruiting | Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent High-grade Glioma | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480941) |
| March 17, 2026 | NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma | Sunnybrook Health Sciences Centre | Phase 2 | Recruiting | Glioblastoma | 118 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476794) |
| March 16, 2026 | NCT07472387 | Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas | Assistance Publique - Hôpitaux de Paris | Not applicable | Not yet recruiting | Glioblastoma (GBM) | 40 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472387) |
| March 12, 2026 | NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Mayo Clinic | Phase 1/2 | Recruiting | Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma... | 33 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468136) |
| March 11, 2026 | NCT07464925 | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | Tetragon Biosciences Ltd | Phase 1 | Recruiting | Glioblastoma Multiforme of Brain, Glioma, Glioblastoma | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464925) |
| March 10, 2026 | NCT07462507 | Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using \[C-11\]-CS1P1 | Washington University School of Medicine | Phase 2 | Recruiting | Central Nervous System Cancer, Brain Metastases | 104 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462507) |
| March 10, 2026 | NCT07461948 | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients | Jonsson Comprehensive Cancer Center | Phase 3 | Recruiting | Glioblastoma | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07461948) |
| March 9, 2026 | NCT07459101 | UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4 | Sunnybrook Health Sciences Centre | Not applicable | Recruiting | Glioblastoma (GBM), Astrocytoma, Grade IV | 120 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459101) |
| March 6, 2026 | NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM) | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455045) |
| March 5, 2026 | NCT07452458 | Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype... | NRG Oncology | Phase 3 | Recruiting | Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | 398 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07452458) |
| March 4, 2026 | NCT07448480 | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas | Blokhin's Russian Cancer Research Center | Observational | Active not recruiting | Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma | 1,000 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448480) |
| March 2, 2026 | NCT07443176 | FCI-Glioblastoma Study | University of Aberdeen | Observational | Not yet recruiting | Glioblastom WHO Grade 4 | 18 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443176) |
| February 27, 2026 | NCT07439172 | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. | Cooper Norcross Health | Phase 2 | Recruiting | High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439172) |
| February 24, 2026 | NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With... | Starlight Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Glioblastoma (GBM) | 68 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431216) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Mayo Clinic | 8 | July 16, 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 6 | June 25, 2026 |
| City of Hope Medical Center | 5 | August 27, 2026 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 | October 1, 2026 |
| Washington University School of Medicine | 4 | June 2, 2026 |
| Medical University of Warsaw | 4 | March 23, 2026 |
| Olivia Newton-John Cancer Research Institute | 3 | October 30, 2026 |
| Copenhagen University Hospital, Rigshospitalet | 3 | May 15, 2026 |
| Beijing Biotech | 3 | April 24, 2026 |
| Sunnybrook Health Sciences Centre | 3 | March 17, 2026 |
| Beijing Tiantan Hospital | 2 | October 14, 2026 |
| Alpheus Medical, Inc. | 2 | October 7, 2026 |
| NuvOx LLC | 2 | August 5, 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 | June 16, 2026 |
| Myosin Therapeutics Inc. | 2 | May 22, 2026 |
| Peking University Third Hospital | 2 | April 27, 2026 |
| University Hospital, Essen | 2 | April 23, 2026 |
| Huashan Hospital | 2 | April 20, 2026 |
| Jecho Biopharmaceuticals Co., Ltd. | 2 | March 30, 2026 |
| Nader Sanai | 2 | March 20, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 54 | October 9, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 43 | October 7, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 40 | October 22, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 33 | October 8, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 28 | October 28, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 19 | October 30, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 6 | March 10, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 2 | October 14, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 1 | April 23, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 86 | October 20, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 40 | October 14, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 11 | October 9, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 10 | June 12, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 8 | October 30, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 7 | September 22, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 6 | October 22, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 6 | June 1, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 5 | June 25, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 5 | May 15, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 5 | August 13, 2025 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 4 | October 9, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 4 | March 17, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 3 | October 9, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 3 | September 21, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 3 | January 23, 2026 |
| [Ireland](https://specstream.ai/data/clinical-trials/country/ireland) | 2 | July 28, 2026 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 2 | June 4, 2026 |
| [Russia](https://specstream.ai/data/clinical-trials/country/russia) | 2 | March 4, 2026 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 2 | April 6, 2025 |
| Reunion | 1 | October 8, 2026 |
| [Puerto Rico](https://specstream.ai/data/clinical-trials/country/puerto-rico) | 1 | August 21, 2026 |
| [India](https://specstream.ai/data/clinical-trials/country/india) | 1 | June 29, 2026 |
| [Indonesia](https://specstream.ai/data/clinical-trials/country/indonesia) | 1 | May 14, 2026 |
| [Uzbekistan](https://specstream.ai/data/clinical-trials/country/uzbekistan) | 1 | April 13, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).